Introduction {#sec1-0300060515613495}
============

Psoriasis is frequently associated with comorbidities that can affect kidney function, including diabetes mellitus, arterial hypertension and obesity.^[@bibr1-0300060515613495],[@bibr2-0300060515613495]^ Chronic kidney disease (CKD) is characterized by a reduction in glomerular filtration rate (GFR) to \<60 ml/min for ≥3 months.^[@bibr3-0300060515613495]^ CKD affects 10.4% of patients with psoriasis,^[@bibr4-0300060515613495]^ and is associated with an increased risk of cardiovascular disease, renal failure and mortality.^[@bibr5-0300060515613495],[@bibr6-0300060515613495]^ Unlike conventional systemic therapies, anti-tumour necrosis factor (TNF)-α drugs are not believed to affect kidney function,^[@bibr7-0300060515613495]^ although data regarding patients with psoriasis and renal failure are not available. GFR is the best index of renal function, as it assesses the progression of kidney dysfunction.^[@bibr8-0300060515613495]^ The Modification of Diet in Renal Disease (MDRD) algorithm is the most widely used method for estimating GFR.^[@bibr9-0300060515613495],[@bibr10-0300060515613495]^

The objective of this study was to estimate the prevalence of CKD and evaluate variations in renal function in patients with moderate-to-severe chronic plaque psoriasis treated with etanercept (an anti-TNF-α drug).

Patients and methods {#sec2-0300060515613495}
====================

Study population {#sec3-0300060515613495}
----------------

This retrospective cohort study enrolled consecutive patients with moderate-to-severe psoriasis who attended the Section of Dermatology and Venereology, University of Verona. Verona, Italy, between June and December 2014. Inclusion criteria were: aged \>18 years; psoriasis area severity index (PASI)^[@bibr11-0300060515613495]^ score \>10; ongoing continuous treatment with 50 mg/week etanercept for ≥6 months. The study was approved by the internal review board of the Department of Medicine, University of Verona, Verona, Italy. All patients provided written informed consent prior to enrolment.

EGFR calculation {#sec4-0300060515613495}
----------------

Estimated GFR was calculated using the MDRD algorithm^[@bibr9-0300060515613495]^ at baseline and after 6 months' continuous treatment with etanercept. Moderate-to-advanced (stage 3--5) CKD was defined as EGFR \<60 ml/min per 1.73 m^2^.^[@bibr3-0300060515613495]^

Statistical analyses {#sec5-0300060515613495}
--------------------

Data were presented as mean ± SD or *n* (%), and analysed using unpaired *t*-test or χ^2^-test as appropriate. Statistical analyses were performed using SPSS® version 19.0 (SPSS Inc., Chicago, IL, USA) for Windows®, and *P*-values \<0.05 were considered statistically significant.

Results {#sec6-0300060515613495}
=======

The study included 51 patients (35 male/16 female; mean age 53 ± 13 years; age range 35--71 years). Mean body mass index was 27.7 ± 5.1 kg/m^2^. There were 28 patients (54.9%) with psoriatic arthritis, 12 (23.5%) with diabetes, and 25 (49.0%) with hypertension.

The prevalence of moderate-to-advanced (stage 3--5) CKD at baseline was 3.9% (two of 51 patients). EGFR was unaffected by etanercept therapy (83.6 ± 23.9 at baseline vs 82.2 ± 21.6 ml/min per 1.73 m^2^ after 6 months).

Discussion {#sec7-0300060515613495}
==========

Psoriasis is associated with several comorbidities, the presence of which may affect treatment choice and monitoring.^[@bibr12-0300060515613495]^ Patients with moderate-to-severe psoriasis have an increased risk of CKD that is independent of traditional risk factors for renal dysfunction.^[@bibr13-0300060515613495]^ The presence of CKD should be determined before starting systemic treatment in order to avoid the potential worsening of kidney function.^[@bibr5-0300060515613495],[@bibr6-0300060515613495]^ Long-term cyclosporine and, to a lesser extent, methotrexate treatments are known to affect kidney function,^[@bibr14-0300060515613495]^ although anti-TNF-α drugs are not believed to do so. Our study found that GFR was unaffected by 6 months' etanercept treatment.

In conclusion, physicians should be aware of the risk of CKD when providing comprehensive care to patients with moderate-to-severe psoriasis; the use of the MDRD formula can be easily implemented in daily practice.
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